We have developed a rapid and sensitive single-well dual-parametric method introduced in linked RAS nucleotide exchange and RAS/RAF-RBD interaction assays. RAS mutations are frequent drivers of multiple different human cancers, but the development of therapeutic strategies has been challenging. Traditionally, efforts to disrupt the RAS function have focused on nucleotide exchange inhibitors, GTP-RAS interaction inhibitors, and activators increasing GTPase activity of mutant RAS proteins. As the amount of biological knowledge grows, targeted biochemical assays enabling high-throughput screening have become increasingly interesting. We have previously introduced a homogeneous quenching resonance energy transfer (QRET) assay for nucleotide binding studies with RAS and heterotrimeric G proteins. Here, we introduce a novel homogeneous signaling technique called QTR-FRET, which combine QRET technology and time-resolved Förster resonance energy transfer (TR-FRET). The dual-parametric QTR-FRET technique enables the linking of guanine nucleotide exchange factor-induced Eu3+-GTP association to RAS, monitored at 615 nm, and subsequent Eu3+-GTP-loaded RAS interaction with RAF-RBD-Alexa680 monitored at 730 nm. Both reactions were monitored in a single-well assay applicable for inhibitor screening and real-time reaction monitoring. This homogeneous assay enables separable detection of both nucleotide exchange and RAS/RAF interaction inhibitors using low nanomolar protein concentrations. To demonstrate a wider applicability as a screening and real-time reaction monitoring method, the QTR-FRET technique was also applied for G(i)α GTP-loading and pertussis toxin-catalyzed ADP-ribosylation of G(i)α, for which we synthesized a novel γ-GTP-Eu3+ molecule. The study indicates that the QTR-FRET detection technique presented here can be readily applied to dual-parametric assays for various targets.
We have developed a rapid and sensitive single-well dual-parametric method introduced in linked RAS nucleotide exchange and RAS/RAF-RBD interaction assays. RAS mutations are frequent drivers of multiple different humancancers, but the development of therapeutic strategies has been challenging. Traditionally, efforts to disrupt the RAS function have focused on nucleotide exchange inhibitors, GTP-RAS interaction inhibitors, and activators increasing GTPase activity of mutant RAS proteins. As the amount of biological knowledge grows, targeted biochemical assays enabling high-throughput screening have become increasingly interesting. We have previously introduced a homogeneous quenching resonance energy transfer (QRET) assay for nucleotide binding studies with RAS and heterotrimeric G proteins. Here, we introduce a novel homogeneous signaling technique called QTR-FRET, which combine QRET technology and time-resolved Förster resonance energy transfer (TR-FRET). The dual-parametric QTR-FRET technique enables the linking of guanine nucleotide exchange factor-induced Eu3+-GTP association to RAS, monitored at 615 nm, and subsequent Eu3+-GTP-loaded RAS interaction with RAF-RBD-Alexa680 monitored at 730 nm. Both reactions were monitored in a single-well assay applicable for inhibitor screening and real-time reaction monitoring. This homogeneous assay enables separable detection of both nucleotide exchange and RAS/RAF interaction inhibitors using low nanomolar protein concentrations. To demonstrate a wider applicability as a screening and real-time reaction monitoring method, the QTR-FRET technique was also applied for G(i)α GTP-loading and pertussis toxin-catalyzed ADP-ribosylation of G(i)α, for which we synthesized a novel γ-GTP-Eu3+ molecule. The study indicates that the QTR-FRET detection technique presented here can be readily applied to dual-parametric assays for various targets.
Multiple cellular signaling
pathways act through GTP-binding proteins. Small guanosine triphosphatases
(GTPases), including RAS and heterotrimeric G proteins, play an important
role by regulating correct cellular functions.[1,2] The
small GTPase superfamily comprise over 150 human members, which are
divided into five major branches.[3] RAS
superfamily members act as membrane bound switches by cycling between
GDP-bound inactive and GTP-bound active forms.[1,4−6] This switch function is controlled by guanine nucleotide
exchange factors (GEFs) and GTPase-activating proteins (GAPs).[6] Usually, GTPases are functional when in the active
GTP-bound form, enabling interaction with their downstream effectors.[7−9] Apart from small GTPases, for example, RAS, GTP is a critical cofactor
for multiple disease-related signaling pathways, including G protein-coupled
receptors (GPCRs). Heterotrimeric G proteins serve similar switch
functions as RAS and mediate signal transmission via seven transmembrane
domain GPCRs to intracellular effectors.[2,10,11] G proteins are composed of three subunits, α,
β, and γ, from which the α subunit (Gα) works
as a GTP-binding switch. The heterotrimeric G protein cycles between
an inactive GDP-bound conformation, that is primed for interaction
with an activated receptor, and an active GTP-bound conformation,
which can modulate the activity downstream.[2,10,11] Extracellular stimulus of GPCR, having an
exchange factor activity, induces the GDP dissociation from Gα
and subsequent activation of Gα through GTP binding. Gα
forms the constitutive heterotrimer together with Gβ and Gγ
subunits, and the activation of the Gα subunit results in conformational
changes leading to dissociation from the receptor and from Gβγ
subunits. After activation, both Gα subunits and Gβγ
subunits interact downstream with varying specificity.[11,12] G protein GAPs act allosterically on Gα subunits by increasing
intrinsic GTP hydrolysis, but their deactivation is also regulated
by RGS (regulator of G-protein signaling) proteins, which can accelerate
the intrinsic GTPase activity and enable the reformation of heterotrimers.[12]GPCRs are the largest human membrane protein
family and one of
the most common drug targets comprising one-third of all drug sales.[13,14] G proteins themselves are not as widely targeted, but interest against
GPCR downstream targets is increasing.[15] Also, small GTPases and especially KRAS have gained renewed interest
in recent years as a drug target, but so far, their direct targeting
has proved to be challenging.[16−20] Due to the high interest, novel assay methods to study and target
these proteins are constantly being developed. Traditional methods
to study RAS and G proteins have been nucleotide binding assays utilizing
labeled GDP and GTP. In the case of RAS and other small GTPases, radiolabeled
nucleotides have been extensively replaced by fluorophore-conjugated
nucleotides, which are mostly suitable for separation-free detection
based on the properties of the nucleotide conjugated fluorophore,
for example, environment sensitivity or anisotropy changes.[21−25] The search for improved methods is still active, as a panel of methods
has recently been introduced.[26] In the
case of G proteins, the number of suitable methodologies is even more
limited because of the membrane environment. Thus, radiolabels and
heterogeneous assay techniques have not been totally displaced.[27] However, fluorophore-based techniques enabling
homogeneous separation-free detection for G proteins have already
started to replace the conventional heterogeneous techniques.[28−32] Despite the large number of potential methods, advances can be achieved
by improving assay performance or the amount of reliable data produced
within a single assay.Time-resolved fluorescence (TRF) in its
different forms can potentially
answer the need of improved assays. Lanthanide chelates were originally
applied for heterogeneous assays, but newer methods based on chelate
and cryptate structures are mainly homogeneous and often utilized
in time-resolved Förster resonance energy transfer (TR-FRET).[28,33−35] The advantage of TRF signal detection is the increased
signal-to-background (S/B) ratio due to the low background signal
resulting from long-lived fluorescence and time-gated measurements.
In addition, the apparent large Stokes shift simplifies the assay
development, especially for TR-FRET applications. GPCR second messengers
and kinases are nowadays the most popular TR-FRET targets, but as
the assays have been developed for many other targets, TR-FRET has
become the primary technology for many laboratories. The search for
improvements related to TR-FRET detection has been targeted mainly
for improved fluorophore structures. However, especially when multiplexed
assays are developed, multiple labeling steps and spectral overlap
optimization may complicate the assay development and increase the
unwanted background signal.[36] To avoid
multiple labeling steps, native tryptophan moieties have been used
as one signaling moiety to study, for example, GTPases.[37] However, not all proteins contain suitable tryptophan
residues, and thus, monitoring of linked protein–ligand (PLIs)
and protein–protein interactions (PPIs) still rely on label-conjugated
assay components.Previously, we have introduced a single-label
homogeneous quenching
resonance energy transfer (QRET) technique, for example, for small
GTPases and heterotrimeric G proteins, using a Eu3+-chelate
conjugated GTP.[38−40] We have also shown that QRET enables similar analytical
performance as the dual-label TR-FRET.[40] Additionally, we recently introduced quencher modulated time-resolved
Förster resonance energy transfer (QTR-FRET) as a method to
reduce TR-FRET background fluorescence by introducing a soluble quencher
molecule.[41] Now, we introduce the QTR-FRET
method for dual-parametric kinetic studies with KRAS and G(i)α.
QTR-FRET combines the single-label QRET, used now for binding studies
with Eu3+-GTP and protein, with a dual-label TR-FRET method
enabling simultaneous monitoring of two reactions, PLI and PPI. To
demonstrate the analytical performance of the QTR-FRET platform, we
monitored Eu3+-GTP association and followed RAF-RBD-Alexa680
binding to Eu3+-GTP-loaded KRAS. Additionally, we studied
γ-GTP-Eu3+ association to G(i)α, which was
linked to monitor pertussis toxin-catalyzed G(i)α ADP-ribosylation.
These assays clearly demonstrated that the QTR-FRET approach can improve
the functionality of the TR-FRET measurements by increasing the S/B
ratio and that two reactions can be monitored simultaneously by using
only two labeled molecules and a soluble quencher.
Experimental
Section
Kinetic Monitoring of KRAS Nucleotide Exchange and KRAS/RAF-RBD
Interaction
Detailed lists of materials and instrumentation,
cloning, production, and purification of KRAS and related proteins
(Figures S1 and S2), Alexa680 conjugations,
and γ-GTP-Eu3+ synthesis (Figures S3–S5) are presented in the Supporting Information (SI). In addition, detailed protocols for KRAS/RAF-RBD
interaction concentration optimization, KRAS enzymatic glycosylation,
and data analysis are presented in the SI. All presented assays were performed in triplicate unless otherwise
indicated.We selected 50 and 200 nM KRAS for further nucleotide
association and protein–protein interaction monitoring. Assays
were performed using protocol 1 in a 15 μL final volume. First,
we assayed two known KRAS-inhibiting designed ankyrin repeat proteins
(DARPins) to monitor their functional concentrations.[42] DARPins (K27 and K55) were titrated up to 20 μM in
a reaction with KRAS (200 nM), Eu3+-GTP (25 nM), MG (24
μM), and SOScat (10 nM). Signals were monitored 15
min after SOScat addition, following RBD-Alexa680 (25 nM)
addition and a second measurement after 15 min. DARPins K27 and K55
were thereafter used in single selected concentrations. KRAS was incubated
with K27 (500 nM) and K55 (5 μM) for 10 min in a 7 μL
volume. Detection solution (6 μL) containing Eu3+-GTP (25 nM), MG (24 μM), and RBD-Alexa680 (25 nM) was added,
and signals were monitored after 5 min at 615 and 730 nm. Nucleotide
association and KRAS/RAF-RBD interaction were launched by 10 nM SOScat (2 μL), and signals were monitored during a 60 min
incubation at RT. Thereafter, nucleotide association and KRAS/RAF-RBD
interaction were separated. Again, KRAS was incubated with K27 and
K55 for 10 min. A QRET detection solution (4 μL) containing
Eu3+-GTP (25 nM) and MG (24 μM) was added, and signals
were monitored. After 10 nM SOScat (2 μL) addition,
signals were kinetically monitored for 1000 s, before 25 nM of RBD-Alexa680
(2 μL) was added, and signal monitoring was continued for 20
min.
G(i)α ADP-Ribosylation
Protocols for synthesis,
characterization, and functionality testing of γ-GTP-Eu3+ are presented in the SI (Figures S3–S6). In the enzymatic assays with G(i)α (Figure S7), 150 nM G(i)α and various Pertussis toxin (PTX, recombinant
form of the PTX S1-subunit)[43,44] concentrations (0–600
nM) were used. An ADP-ribosylation reaction (60 min, RT) was performed
at a 4.5 μL volume, using an EDTA-containing assay buffer and
bio-NAD+ (25 nM). γ-GTP-Eu3+ (25 or 50
nM) was added together with 0 or 10 μM GTP in a MgCl2-containing assay buffer, enabling γ-GTP-Eu3+ loading
monitored at 615 and 730 nm (30 min). Thereafter, 25 nM SA-Alexa680
was added, and signals were monitored multiple times during a 90 min
incubation at a 15 μL volume. Finally, MG (20 or 35 μM)
was added, and signals were further monitored at a 17 μL volume
after 30 min of incubation.
Results and Discussion
In nature, many enzymatic reactions are coupled with other reactions
occurring simultaneously or in a specific order. Currently, the methods
enabling simultaneous detection of multiple reactions are scarce.
Previously, we introduced a method named as QTR-FRET, which was demonstrated
to reduce background signals in TR-FRET assays.[41] QTR-FRET combines the TR-FRET-type energy transfer between
lanthanide chelate (donor) and acceptor fluorophore and the use of
soluble quencher, here malachite green (MG), to reduce the signal
from the nonbound Ln3+ ligand following the QRET principle.
When lanthanide chelate, for example, Eu3+-chelate, is
conjugated to a small molecule, it enables the detection of PLI in
the presence of a soluble quencher as shown earlier with multiple
different targets monitored using the QRET technique.[45] Energy transfer processes are not self-excluding, and thus,
the second reaction between Eu3+-chelate and an acceptor-conjugated
molecule can be monitored from a single well (Figure ). In this work, we studied Eu3+-GTP binding to KRAS in the coupled reaction to monitor active KRAS
interaction with RAF-RBD-Alexa680. In the assay, the reaction can
be inhibited in two steps: (1) SOScat-induced KRAS activation
and (2) KRAS-GTP interaction with RAF-RBD. These reactions can be
monitored from a single well in real time (Figure ). To demonstrate the wider applicability
of the QTR-FRET technique, we also monitored G(i)α ADP-ribosylation
and simultaneous loading with γ-GTP-Eu3+ (Figure S7).
Figure 1
Dual-parametric nucleotide exchange and
RAS/RAF-RBD interaction
assay based on the QTR-FRET principle. In the nucleotide exchange,
RAS-bound GDP is dissociated in the presence of GEF (SOScat), enabling Eu3+-GTP association. Bound Eu3+-GTP is protected from the soluble quencher (MG), and an increase
in TRF signal is monitored at 615 nm. Formation of Eu3+-GTP-RAS enables RBD-Alexa680 binding, and an increased TR-FRET signal
is monitored at 730 nm. Inhibitors can block either Eu3+-GTP association, resulting low signals in TRF- and TR-FRET measurements,
or the RAS/RAF-RBD interaction, rendering an unaffected TRF signal
but low TR-FRET signal. Additionally, MG lowers the Eu3+-GTP ensuing background signal in TR-FRET measurements, thus providing
an improved S/B ratio. The QTR-FRET principle enables simultaneous
and discriminating protein–ligand (PLI) and protein–protein
interaction (PPI) inhibitor selections in a coupled real-time assay.
Dual-parametric nucleotide exchange and
RAS/RAF-RBD interaction
assay based on the QTR-FRET principle. In the nucleotide exchange,
RAS-bound GDP is dissociated in the presence of GEF (SOScat), enabling Eu3+-GTP association. Bound Eu3+-GTP is protected from the soluble quencher (MG), and an increase
in TRF signal is monitored at 615 nm. Formation of Eu3+-GTP-RAS enables RBD-Alexa680 binding, and an increased TR-FRET signal
is monitored at 730 nm. Inhibitors can block either Eu3+-GTP association, resulting low signals in TRF- and TR-FRET measurements,
or the RAS/RAF-RBD interaction, rendering an unaffected TRF signal
but low TR-FRET signal. Additionally, MG lowers the Eu3+-GTP ensuing background signal in TR-FRET measurements, thus providing
an improved S/B ratio. The QTR-FRET principle enables simultaneous
and discriminating protein–ligand (PLI) and protein–protein
interaction (PPI) inhibitor selections in a coupled real-time assay.
QTR-FRET Enables Dual-Parametric Eu3+-GTP Association
and KRAS/RAF-RBD Interaction Monitoring
The RAF protein is
a serine/threonine kinase and downstream interactor of RAS, which
occurs through RAF-RBD, binding exclusively to active GTP-RAS with
a reported Kd of approximately 20 nM.[7−9,46] In addition to biological importance,
this GTP-RAS-specific binding has been utilized in many assays to
study RAS.[42] We selected the GTP-RAS-dependent
binding of RAF-RBD as a model to demonstrate the QTR-FRET principle
in a dual-parametric assay, monitoring nucleotide exchange and GTP-RAS
interaction with RAF-RBD in a single well. Simultaneous monitoring
is especially beneficial for inhibitor screening, as effects on a
nucleotide binding state can be monitored through Eu3+-GTP
(615 nm), and inhibition of either nucleotide exchange or RAS/RAF-RBD
interaction is measured from the Alexa680 channel at 730 nm (Figure ).To prove
the QTR-FRET assay functionality, we first performed KRAS titration
(0–600 nM) using fixed SOScat (10 nM) and RBD-Alexa680
(25 nM) concentrations. The assay was performed using two protocols
with varying detection: (1) Eu3+-GTP (25 nM) and MG (24
μM) were premixed and added simultaneously, or (2) Eu3+-GTP was added first, followed by addition of MG. Using the first
protocol, the TRF signal at 615 nm could be monitored in real time,
and only a minor increase in the signal was observed after RBD-Alexa680
addition (Figure S8A). Using the second
protocol, S/B ratios without MG were low, but the introduction of
MG dramatically increased the S/B ratio to 12 (Figure S8B).We also monitored TR-FRET signals at 730
nm to measure the RAS/RAF-RBD
interaction using the two given protocols. Using protocol 1, a clear
TR-FRET signal increase was detected in KRAS titration after Alexa680-RBD
addition (Figure S8C). Without RBD-Alexa680,
the S/B ratio compared to the GDP-blocked reaction was 2.3, which
stems from the Eu3+-GTP signal protection upon binding
to KRAS. This protection could also be seen at 730 nm, although the
signal levels were very low. However, with RBD-Alexa680, the monitored
S/B ratio was 10, clearly demonstrating the interaction between Eu3+-GTP loaded KRAS and RBD-Alexa680. The TR-FRET signal was
also monitored without a quencher, as shown with protocol 2 (Figure S8D). Without MG and RBD-Alexa680, the
S/B ratio was minimal, and the addition of RBD-Alexa680 did not dramatically
improve the monitored S/B ratio. Even though the KRAS-dependent TR-FRET
signal between Eu3+-GTP and RBD-Alexa680 is clear, a high
background signal, also in the presence of GDP, was detected with
the used concentrations. By adding MG, this high background level
was reduced approximately 5-fold, whereas the specific TR-FRET signal
was reduced by less than 2-fold. This improved the S/B ratio from
2.2 to 5.9, respectively. Given the higher S/B ratios and utility
of real-time monitoring when following protocol 1 (Eu3+-GTP added in complex with MG), it was selected for all further assays.
On the basis of these results, we also kept the KRAS concentration
at 200 nM or lower in subsequent assays. The selected low nM concentrations
are in accordance to the ones used previously in RAS/RAF interaction
assays utilizing TR-FRET.[42,47]
Eu3+-GTP Association
and KRAS/RAF-RBD Interaction
Can Be Monitored in Real Time
Next, we tested the functionality
of the assay in a real-time measurement by monitoring Eu3+-GTP association and KRAS/RAF-RBD interaction. To demonstrate the
biologically relevant functionality of the assay we selected two recently
demonstrated DARPins as a tool compounds for specific KRAS inhibition.[42] First, saturating concentrations for GDP-RAS-specific
DARPin K27 and GTP-RAS-specific DARPin K55 were determined (Figure S9).[42] On the
basis of the DARPin titration, we selected 0.5 μM and 5 μM
as saturating concentrations for K27 and K55, respectively. Using
these concentrations, we assayed the association and KRAS/RAF-RBD
interaction separately by adding RBD-Alexa680 after near maximal Eu3+-GTP loading (Figure ). We observed increased TRF signals (615 nm) without DARPin
and with K55, compared to the reactions without SOScat or
with K27. This reflects complete blocking of a nucleotide exchange
by K27 but not with K55. In all cases, the RBD-Alexa680 addition did
not dramatically change the signal observed at 615 nm (Figure A). On the other hand, TR-FRET
signals monitored at 730 nm, which were low in all cases before RBD-Alexa680
addition, increased after RBD-Alexa680 addition in reactions with
SOScat but without DARPins (Figure B). When TR-FRET signals were compared before
and after RBD-Alexa680 addition, the S/B ratio of 7.4 was achieved
after 10 min of incubation. When the reaction was compared to the
reactions without SOScat or with SOScat and
in the presence of K27 or K55, the observed S/B ratios were 1.7, 1.5,
and 1.8, respectively. This reflects no RBD-Alexa680 interaction with
KRAS. These results are consistent with the notion that K27 inhibits
the Eu3+-GTP association to KRAS, and thereafter, the RBD-Alexa680
interaction cannot occur. Additionally, K55 allows Eu3+-GTP association, but blocks the KRAS interaction with RBD-Alexa680
(Figure ).[42]
Figure 2
Real-time monitoring of the coupled nucleotide association
and
KRAS/RAF-RBD interaction with DARPins K27 and K55. Eu3+-GTP (25 nM) association and RBD-Alexa680 interaction were monitored
at 340/615 nm (A) and 340/730 nm (B) in the absence (red) or presence
of 10 nM SOScat (black) or reactions with SOScat and selected DARPin, K27 (blue) or K55 (magenta). Eu3+-GTP association kinetics were first monitored after SOScat addition, and monitoring was continued similarly after RBD-Alexa680
(25 nM) addition. Data represent mean ± SD (n = 3).
Real-time monitoring of the coupled nucleotide association
and
KRAS/RAF-RBD interaction with DARPins K27 and K55. Eu3+-GTP (25 nM) association and RBD-Alexa680 interaction were monitored
at 340/615 nm (A) and 340/730 nm (B) in the absence (red) or presence
of 10 nM SOScat (black) or reactions with SOScat and selected DARPin, K27 (blue) or K55 (magenta). Eu3+-GTP association kinetics were first monitored after SOScat addition, and monitoring was continued similarly after RBD-Alexa680
(25 nM) addition. Data represent mean ± SD (n = 3).Next we performed combined real-time
measurements using a reaction
where both Eu3+-GTP and RBD-Alexa680 were present before
the SOScat addition. These assays confirmed the observation
that K27 blocks both nucleotide exchange and subsequent KRAS/RAF-RBD
interaction, but K55 blocks only the interaction between Eu3+-GTP-loaded KRAS and RBD-Alexa680 (Figures and 3). As the Eu3+-GTP association is slower than the subsequent interaction
with RBD-Alexa680, kinetics in both 615 nm (Figure A) and 730 nm (Figure B) channels primarily report the slower reaction,
explaining the short lag phase seen at 730 nm. The assay performed
with 50 nM KRAS showed nearly identical results as the assay with
200 nM KRAS but only with a decreased S/B ratio (data not shown).
With 50 nM KRAS, especially the TR-FRET signal level monitored at
730 nm was compromised. These results clearly indicate that the single-well
QTR-FRET assay can be used, instead of two separate assays, to monitor
nucleotide exchange and KRAS/RAF-RBD interactions at the same time
in real time.
Figure 3
Single-well real-time monitoring of coupled nucleotide
association
and KRAS/RAF-RBD interaction reactions with DARPins K27 and K55. Eu3+-GTP (25 nM) association at 340/615 nm (A) and KRAS/RAF-RBD
interaction at 340/730 nm (B) were kinetically monitored in a single
reaction with KRAS (200 nM) and RBD-Alexa680 (25 nM) after SOScat (10 nM) addition. Reaction without SOScat (black)
showed no signal increase over time, while a fast TRF signal increase
is observed with SOScat (red) followed by a slightly delayed
TR-FRET increase. K27 (blue) blocks totally the nucleotide exchange
and subsequent RBD-Alexa680 interaction, showing no TR-FRET or TRF
signal increase, as K55 (magenta) blocked only the RBD-Alexa680 interaction,
with only a minor effect to the TRF signal observed. All measurements
were performed in the presence of 24 μM MG. Data represent mean
± SD (n = 3).
Single-well real-time monitoring of coupled nucleotide
association
and KRAS/RAF-RBD interaction reactions with DARPins K27 and K55. Eu3+-GTP (25 nM) association at 340/615 nm (A) and KRAS/RAF-RBD
interaction at 340/730 nm (B) were kinetically monitored in a single
reaction with KRAS (200 nM) and RBD-Alexa680 (25 nM) after SOScat (10 nM) addition. Reaction without SOScat (black)
showed no signal increase over time, while a fast TRF signal increase
is observed with SOScat (red) followed by a slightly delayed
TR-FRET increase. K27 (blue) blocks totally the nucleotide exchange
and subsequent RBD-Alexa680 interaction, showing no TR-FRET or TRF
signal increase, as K55 (magenta) blocked only the RBD-Alexa680 interaction,
with only a minor effect to the TRF signal observed. All measurements
were performed in the presence of 24 μM MG. Data represent mean
± SD (n = 3).
KRAS activity is regulated on many
levels, including through post-translational modifications.[4,5] In addition to prenylation of the CAAX-motif, KRAS can also be,
for example, glycosylated.[48] Bacterial
toxin TpeL is one of the enzymes which monoglycosylates small GTPases
from the switch I domain (Thr35), and it is reported to prevent the
KRAS interaction with RAF-RBD.[48] TpeL was
selected for QTR-FRET glycosylation assays, which were performed with
GDP- or GMPPNP-loaded KRAS and two UDP-sugar donors, UDP-GlcNAc and
UDP-Glu. TpeL has reported to not prefer a KRAS activity state but
prefers UDP-GlcNAc over UDP-Glu.[48] The
QTR-FRET assay confirmed the TpeL UDP-GlcNAc preference, which was
30-fold over UDP-Glu, but it also showed a 10-fold preference to GDP-KRAS
over GMPPNP-KRAS when monitored at 615 nm (Figure A, Table S1).
In the assay with GMPPNP-KRAS, TpeL could not completely inhibit the
nucleotide exchange with either one of the used UDP-sugars, but the
level of glycosylation with UDP-GlcNAc was again higher. This observed
GDP-KRAS-preferring behavior of TpeL is similar as reported with TpeL-related
glycosylating toxin, the lethal toxin of Clostridium
sordellii.[49,50] As TpeL KRAS glycosylation
is reported as a KRAS/RAF-RBD interaction blocker and not for nucleotide
exchange, QTR-FRET results from the nucleotide exchange were further
confirmed with a conventional QRET nucleotide exchange assay. QRET
assay results were in line with the ones from QTR-FRET and confirmed
the enzyme preference to UDP-GlcNAc and GDP-KRAS (Figure S10, Table S1). As TpeL blocked the nucleotide exchange,
leading to a prevented KRAS/RAF-RBD interaction, no further information
using QTR-FRET was observed compared to traditional QRET, when the
KRAS/RAF-RBD interaction was monitored at 730 nm (Figure S11).
Figure 4
Dual-parametric
KRAS glycosylation assay. (A) TpeL-catalyzed KRAS
glycosylation was studied with two UDP-sugars (25 μM) and KRAS
(200 nM) loaded with GDP or GMPPNP. After a 30 min TpeL reaction,
an Eu3+-GTP (25 nM) exchange was performed with SOScat (10 nM), and signals were monitoring at 615 nm. With GDP-KRAS,
UDP-GlcNAc (black) was preferred over UDP-Glu (blue) as seen from
the efficient nucleotide exchange blocking. Similarly, UDP-GlcNAc
(red) was preferred over UDP-Glu (magenta) when the assay was performed
with GMPPNP-KRAS. (B) When the TpeL titration using UDP-GlcNAc was
performed after SOScat-induced KRAS loading with Eu3+-GTP (black) or Eu3+-GDP (red), clear KRAS/RAF-RBD
interaction blocking could be monitored at 730 nm. With Eu3+-GDP, no TR-FRET signal was monitored after RBD-Alexa680 (25 nM)
addition as the KRAS/RAF-RBD interaction cannot occur. KRAS loading
with Eu3+-GTP enabled the KRAS/RAF-RBD interaction, which
was blocked in a TpeL concentration-dependent manner. Data represent
mean ± SD (n = 3).
Dual-parametric
KRAS glycosylation assay. (A) TpeL-catalyzed KRAS
glycosylation was studied with two UDP-sugars (25 μM) and KRAS
(200 nM) loaded with GDP or GMPPNP. After a 30 min TpeL reaction,
an Eu3+-GTP (25 nM) exchange was performed with SOScat (10 nM), and signals were monitoring at 615 nm. With GDP-KRAS,
UDP-GlcNAc (black) was preferred over UDP-Glu (blue) as seen from
the efficient nucleotide exchange blocking. Similarly, UDP-GlcNAc
(red) was preferred over UDP-Glu (magenta) when the assay was performed
with GMPPNP-KRAS. (B) When the TpeL titration using UDP-GlcNAc was
performed after SOScat-induced KRAS loading with Eu3+-GTP (black) or Eu3+-GDP (red), clear KRAS/RAF-RBD
interaction blocking could be monitored at 730 nm. With Eu3+-GDP, no TR-FRET signal was monitored after RBD-Alexa680 (25 nM)
addition as the KRAS/RAF-RBD interaction cannot occur. KRAS loading
with Eu3+-GTP enabled the KRAS/RAF-RBD interaction, which
was blocked in a TpeL concentration-dependent manner. Data represent
mean ± SD (n = 3).To study if glycosylation would also block
the KRAS/RAF-RBD interaction, we modified the QTR-FRET assay scheme
by performing the nucleotide exchange with either Eu3+-GTP
or Eu3+-GDP before the TpeL reaction. The assay confirmed
the expected KRAS/RAF-RBD interaction blocking in TpeL titration with
UDP-GlcNAc (Figure B). It also proved the correct assay functionality as no TR-FRET
signal was observed after RBD-Alexa680 addition if Eu3+-GDP was used in KRAS nucleotide loading. Nucleotide association
with Eu3+-GTP or Eu3+-GDP was equal, and the
glycosylation could not be monitored based on the TRF signal at 615
nm (data not shown). The important role of the KRAS switch I domain
on PPI has already been known, and on the basis of our data, the glycosylation
of Thr35 seems to block not only the KRAS interaction with RAF-RBD
but also with SOScat.[51]
Dual Parametric QTR-FRET Technique Can Be Readily Converted
for Different Targets and Reactions
Assays performed with
KRAS already proved the functionality of the QTR-FRET technique for
the biochemical studies and as a potential inhibitor screening tool.
To further highlight the QTR-FRET technique applicability for different
targets, we performed a dual-parametric assay on PTX-catalyzed ADP-ribosylation
of G(i)α, a heterotrimeric GTP-binding monomer. Pertussis toxin
is composed of five noncovalently bound subunits (PtxS1–S5),
which are arranged in an AB5-type configuration.[43] The QTR-FRET assay utilized a recombinant form of the PtxS1
subunit, which is the PTX subunit responsible for G(i)α ADP-ribosylation.[43,44] As Eu3+-GTP used with KRAS (2′/3′-labeled)
has too low of an affinity to Gα proteins, a novel γ-GTP-Eu3+ molecule was prepared for this purpose (Figures S3–S5).[52] The new
γ-GTP-Eu3+ was first tested for G(i)α binding,
and the determined binding affinity was 25 ± 1 nM in the used
QRET assay with 20 nM G(i)α (Figure S6). On the basis of these results, the newly introduced γ-GTP-Eu3+ binds to G(i)α at the expected affinity, and at least
in the current system, the functionality of the molecule is improved
compared to the previously introduced nonhydrolyzable GTP analog (Eu-GTP).[40,52]Next, the QTR-FRET assay was utilized to detect PTX-catalyzed
ADP-ribosylation of G(i)α. Here, G(i)α was loaded with
γ-GTP-Eu3+ using the MgCl2/EDTA exchange,
and biotin-NAD+ reacted with the G(i)α protein in
the reaction with PTX (Figure S7). PTX
titration (0–600 nM) was performed under constant conditions
using 150 nM G(i)α and 25 nM biotin-NAD+. Thereafter,
G(i)α was loaded with two concentrations of γ-GTP-Eu3+ (25 or 50 nM), and ADP-ribosylation was monitored in the
presence of SA-Alexa680 and MG. When ADP-ribosylation was monitored
at 730 nm, a clear increase in the background signal was monitored
with the increased γ-GTP-Eu3+ concentration (Figure A). This background
signal was decreased by MG, as observed from the S/B ratios calculated
by comparing the signal of the GTP-blocked reaction before and after
MG addition (Figure B). With 25 nM γ-GTP-Eu3+, monitored S/B ratios
before and after MG were 4.3 and 6.0, respectively. As expected, the
effect of MG was higher with 50 nM γ-GTP-Eu3+, where
the S/B ratio was increased from 3.8 to 7.4, respectively (Figure B). Eu3+ signals (615 nm) from the same reactions were also monitored to
confirm that the increased PTX concentration had no effect on TRF
signal levels (Figure C). Thus, the TRF signal increase was solely due to γ-GTP-Eu3+ loading. The S/B ratio increased along with the increasing
γ-GTP-Eu3+ concentration, as the G(i)α loading
was more complete (Figure D). This increase in G(i)α loading also explains the
improved functionality monitored with 50 nM γ-GTP-Eu3+ using the channel at 730 nm and the QTR-FRET protocol with MG (Figure ). In all the assays,
γ-GTP-Eu3+ and MG were added separately to identify
the effect of each individual component. However, as seen with KRAS,
the addition of preformed γ-GTP-Eu3+ and the MG mixture
solution can improve the QTR-FRET functionality further (data not
shown).
Figure 5
Dual-parametric G(i)α
assay for γ-GTP-Eu3+ association and ADP-ribosylation
monitoring. (A) PTX catalyzed G(i)α ADP-ribosylation was studied
with biotin-NAD+ and SA-Alexa680 as a TR-FRET acceptor.
ADP-ribosylated and non-ADP-ribosylated G(i)α were loaded with
25 (red and black) or 50 nM (magenta and blue) γ-GTP-Eu3+ using MgCl2/EDTA exchange, and TR-FRET signals
at 730 nm were monitored before (solid) and after (dashed) MG addition.
(B) Signal-to-background (S/B) ratio was significantly improved upon
MG addition (solid vs dashed) with 25 (black) and 50 nM (red) γ-GTP-Eu3+ concentrations. (C) No differences in the QRET signals,
monitoring γ-GTP-Eu3+ association at 615 nm, were
detected between ADP-ribosylated (dashed) and non-ADP-ribosylated
(solid) G(i)α using 25 (black) or 50 nM (blue) Eu3+-GTP. γ-GTP-Eu3+ association could be blocked with
10 μM GTP in both reactions, 25 nM (red) or 50 nM (magenta)
γ-GTP-Eu3+. (D) ADP-ribosylation (dashed) had no
effect on γ-GTP-Eu3+ association (dashed vs solid),
but only γ-GTP-Eu3+ concentration, 25 (black) or
50 nM (red), affected the observed S/B ratio compared to the reaction
blocked with 10 μM GTP. Data represent mean ± SD (n = 3).
Dual-parametric G(i)α
assay for γ-GTP-Eu3+ association and ADP-ribosylation
monitoring. (A) PTX catalyzed G(i)α ADP-ribosylation was studied
with biotin-NAD+ and SA-Alexa680 as a TR-FRET acceptor.
ADP-ribosylated and non-ADP-ribosylated G(i)α were loaded with
25 (red and black) or 50 nM (magenta and blue) γ-GTP-Eu3+ using MgCl2/EDTA exchange, and TR-FRET signals
at 730 nm were monitored before (solid) and after (dashed) MG addition.
(B) Signal-to-background (S/B) ratio was significantly improved upon
MG addition (solid vs dashed) with 25 (black) and 50 nM (red) γ-GTP-Eu3+ concentrations. (C) No differences in the QRET signals,
monitoring γ-GTP-Eu3+ association at 615 nm, were
detected between ADP-ribosylated (dashed) and non-ADP-ribosylated
(solid) G(i)α using 25 (black) or 50 nM (blue) Eu3+-GTP. γ-GTP-Eu3+ association could be blocked with
10 μM GTP in both reactions, 25 nM (red) or 50 nM (magenta)
γ-GTP-Eu3+. (D) ADP-ribosylation (dashed) had no
effect on γ-GTP-Eu3+ association (dashed vs solid),
but only γ-GTP-Eu3+ concentration, 25 (black) or
50 nM (red), affected the observed S/B ratio compared to the reaction
blocked with 10 μM GTP. Data represent mean ± SD (n = 3).
Conclusions
Here,
we have demonstrated the applicability of the QTR-FRET detection
method for dual-parametric HTS compatible assays by monitoring a panel
of KRAS reactions and G(i)α ADP-ribosylation. The QTR-FRET technique
combines the single-label QRET technique with the dual-label TR-FRET
readout, enabling highly sensitive detection of two reactions from
a single well in real-time. TR-FRET is widely used to study PPIs and
PLIs. However, since TR-FRET relies on energy transfer between donor
and acceptor, both conjugated to distinct molecules, multiplexing
of these assays can be challenging. Here, we demonstrated with KRAS
the functionality of QTR-FRET in coupled detection of PLIs and PPIs,
using nonmodified KRAS target protein. The method can be used to separate
inhibitors affecting either GDP- or GMPPNP-KRAS, as shown with specific
DARPins. In addition, we monitored over a 5-fold background signal
reduction with QTR-FRET compared to traditional TR-FRET, which improved
the monitored S/B ratio significantly in the KRAS/RAF-RDB assay. Single-assay
detection showed even improved functionality compared to individual
reactions monitored using QRET or TR-FRET. Similarly in the G(i)α
ADP-ribosylation assay, a clear increase in the S/B ratio was observed
in the presence of MG, and the effect is even more pronounced when
γ-GTP-Eu3+ loading is enhanced by using a higher
concentration of γ-GTP-Eu3+. G proteins possess lower
GTP binding affinity compared to small GTP binding proteins, e.g.,
KRAS, and thus, the preference for higher γ-GTP-Eu3+ concentrations was expected.[52] On the
basis of these results, the QTR-FRET assay can be readily converted
to new targets, and the technique can be beneficial both for reducing
the TR-FRET background and enabling dual-parametric assays. The QTR-FRET
technique is expected to become a valuable and widely used research
tool in the future.
Authors: Kari Kopra; Arjan J van Adrichem; Outi M H Salo-Ahen; Juha Peltonen; Krister Wennerberg; Harri Härmä Journal: Anal Chem Date: 2017-03-29 Impact factor: 6.986
Authors: Dominic Esposito; Andrew G Stephen; Thomas J Turbyville; Matthew Holderfield Journal: Semin Cancer Biol Date: 2018-02-09 Impact factor: 15.707
Authors: David Goricanec; Ralf Stehle; Pascal Egloff; Simina Grigoriu; Andreas Plückthun; Gerhard Wagner; Franz Hagn Journal: Proc Natl Acad Sci U S A Date: 2016-06-13 Impact factor: 11.205
Authors: Daniel A Bonsor; Patrick Alexander; Kelly Snead; Nicole Hartig; Matthew Drew; Simon Messing; Lorenzo I Finci; Dwight V Nissley; Frank McCormick; Dominic Esposito; Pablo Rodriguez-Viciana; Andrew G Stephen; Dhirendra K Simanshu Journal: Nat Struct Mol Biol Date: 2022-09-29 Impact factor: 18.361
Authors: Kari Kopra; Salla Valtonen; Randa Mahran; Jonas N Kapp; Nazia Hassan; William Gillette; Bryce Dennis; Lianbo Li; Kenneth D Westover; Andreas Plückthun; Harri Härmä Journal: Int J Mol Sci Date: 2022-06-26 Impact factor: 6.208
Authors: Pau Castel; Srisathiyanarayanan Dharmaiah; Matthew J Sale; Simon Messing; Gabrielle Rizzuto; Antonio Cuevas-Navarro; Alice Cheng; Michael J Trnka; Anatoly Urisman; Dominic Esposito; Dhirendra K Simanshu; Frank McCormick Journal: Proc Natl Acad Sci U S A Date: 2021-08-17 Impact factor: 11.205
Authors: Alok K Sharma; Marcin Dyba; Marco Tonelli; Brian Smith; William K Gillette; Dominic Esposito; Dwight V Nissley; Frank McCormick; Anna E Maciag Journal: Biomol NMR Assign Date: 2021-10-22 Impact factor: 0.731
Authors: Timothy H Tran; Albert H Chan; Lucy C Young; Lakshman Bindu; Chris Neale; Simon Messing; Srisathiyanarayanan Dharmaiah; Troy Taylor; John-Paul Denson; Dominic Esposito; Dwight V Nissley; Andrew G Stephen; Frank McCormick; Dhirendra K Simanshu Journal: Nat Commun Date: 2021-02-19 Impact factor: 14.919
Authors: Salla Valtonen; Emmiliisa Vuorinen; Taru Kariniemi; Ville Eskonen; John Le Quesne; Martin Bushell; Harri Härmä; Kari Kopra Journal: Anal Chem Date: 2020-11-25 Impact factor: 6.986
Authors: Ville Eskonen; Natalia Tong-Ochoa; Leena Mattsson; Moona Miettinen; Mika Lastusaari; Arto T Pulliainen; Kari Kopra; Harri Härmä Journal: Anal Chem Date: 2020-09-16 Impact factor: 6.986